Heartflow CMO sells 65,153 shares after option exercise
Heartflow, Inc. Chief Medical Officer Campbell Rogers reported option exercises and share sales in HTFL stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Heartflow, Inc. Chief Medical Officer Campbell Rogers reported option exercises and share sales in HTFL stock. On February 12, 2026, he exercised multiple stock options, converting them into common shares at exercise prices of $2.22 and $8.33 per share.
On the same date, he then sold 65,153 shares of common stock in open-market transactions at a weighted average price of $24.4883 per share, under a Rule 10b5-1 trading plan adopted on September 12, 2025. After these transactions, he held 76,034 shares directly, with additional indirect holdings reported in several family and personal trusts.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 39,709 | $0.00 | $0.00 |
| Exercise | Stock Option | 19,401 | $0.00 | $0.00 |
| Exercise | Stock Option | 7,906 | $0.00 | $0.00 |
| Exercise | Common Stock | 19,401 | $2.22 | $43K |
| Exercise | Common Stock | 39,709 | $8.33 | $331K |
| Exercise | Common Stock | 7,906 | $2.22 | $18K |
| Sale | Common Stock | 65,153 | $24.4883 | $1.60M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (6)
- F1. The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.
- F2. The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.
- F3. Includes the sale of 17,538 shares of common stock held and the option exercise and sale of 47,615 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 12, 2025.
- F4. This transaction was executed in multiple trades at price ranging from $22.90 to $26.51. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. These stock options are fully exercisable.
- F6. The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
